drugset
drugset / Trial / NCT05753189

Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

NCT05753189 ↗

Phase 3 Completed 362 enrolled LENZ Therapeutics, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

Safety Study of the Long-Term Safety of LNZ100 \& LNZ101 in Presbyopic Subjects

Timeline

Start
2023-02-21
Primary completion
2024-02-09
Completion
2024-02-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aceclidine Small molecule — Other
Subject Brimonidine Small molecule — Other

Indications

presbyopia